4. Эйкозаноиды (обзорная статья). Козатриеновой кислоты, резолвины, протектины, марезин и эндоканнабиноиды оказывают противовоспалительное и цитопро
 Скачать 391.45 Kb.
|
|
Arthritis Rheum. 2004 Dec;50(12):3925-33. 88. Benabdoune H, Rondon EP, Shi Q, et al. The role of resolvin D1 in the regulation of inflammatory and catabolic mediators in osteoarthritis. Inflamm Res. 2016 Aug;65(8): 635-45. doi: 10.1007/s00011-016-0946-x. Epub 2016 Apr 7. 89. La Porta C, Bura SA, Negrete R, Maldonado R. Involvement of the endo- cannabinoid system in osteoarthritis pain. Eur J Neurosci. 2014 Feb;39(3):485-500. doi: 10.1111/ejn.12468. 90. Burston JJ, Sagar DR, Shao P, et al. Cannabinoid CB2 receptors regulate central sensitization and pain responses associated with osteoarthritis of the knee joint. PLoS One. 2013 Nov 25;8(11):e80440. doi: 10.1371/ journal.pone.0080440. eCollection 2013. 91. Sheibanie AF, Tadmori I, Jing H, et al. Prostaglandin E2 induces IL-23 production in bone marrow-derived dendritic cells. FASEB J. 2004 Aug;18(11):1318-20. Epub 2004 Jun 4. 92. Haroon N. Ankylosis in ankylosing spondylitis: current concepts. Clin Rheumatol. 2015 Jun;34(6):1003-7. doi: 10.1007/s10067- 015-2956-4. 93. Tan S, Wang R, Ward MM. Syndesmophyte growth in ankylosing spondylitis. Curr Opin Rheumatol. 2015 Jul;27(4):326-32. doi: 10.1097/BOR. 0000000000000179. 94. de Vlam K, Lories RJ, Luyten FP. Mechanisms of pathologic new bone forma- tion. Curr Rheumatol Rep. 2006 Oct;8(5):332-7. 95. Каратеев АЕ, Эрдес ШФ. Применение нестероидных противовоспалительных препаратов при анкилозирующем спондилите долго и упорно Терапевтический архив. 2014;(11):123-7. [Karateev AE, Erdes ShF. The use of nonsteroidal antiin- flammatory drugs in ankylosing spondylitis: long and hard! Terapevticheskii arkhiv. 2014;86(11):123-7. (In Russ.)] . 96. Brune K, Patrignani P. New insights into the use of currently available non-steroidal anti-inflammatory drugs. J Pain Res. 2015 Feb 20;8:105-18. doi: 10.2147/JPR.S75160. eCollection 2015. 97. Diaz-Gonzalez F, Sanchez-Madrid F. NSAIDs: learning new tricks from old drugs. Eur J Immunol. 2015 Mar;45(3):679-86. doi: 10.1002/eji.201445222. Epub 2015 Jan 21. 98. Vecchio AJ, Malkowski MG. The struc- tural basis of endocannabinoid oxygenation by cyclooxygenase-2. J Biol Chem. 2011 Jun 10;286(23):20736-45. doi: 10.1074/jbc.M111. 230367. Epub 2011 Apr 13. 99. Vecchio AJ, Simmons DM, Malkowski MG. Structural basis of fatty acid substrate binding to cyclooxygenase-2. J Biol Chem. 2010 Jul 16;285(29):22152-63. doi: 10.1074/jbc. M110.119867. Epub 2010 May 12. 100. Xu S, Rouzer CA, Marnett LJ. Oxicams, a class of nonsteroidal anti-inflammatory drugs and beyond. IUBMB Life. 2014 Dec; 66(12):803-11. doi: 10.1002/iub.1334. Epub 2014 Dec 23. 101. Gates BJ, Nguyen TT, Setter SM, Davies NM. Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety. Expert Opin Pharmacother. 2005 Oct;6(12):2117-40. 102. Каратеев АЕ. Мелоксикам: золотая середина нестероидных противовоспалительных препаратов. Терапевтический архив meta-analysis and systematic review of randomized controlled trials. Am J Med. 1999 Dec 13;107(6A): 48S-54S. 104. Asghar W, Jamali F. The effect of COX-2- selective meloxicam on the myocardial, vas- cular and renal risks: a systematic review. Inflammopharmacology. 2015 Feb;23(1):1-16. doi: 10.1007/s10787-014-0225-9. Epub 2014 Dec 17. 105. Iyer JP, Srivastava PK, Dev R, et al. Prostaglandin E(2) synthase inhibition as a therapeutic target. Expert Opin Ther Targets. 2009 Jul;13(7):849-65. doi: 10.1517/ 14728220903018932. 106. Mbalaviele G, Pauley AM, Shaffer AF, et al. Distinction of microsomal prostaglandin E synthase-1 (mPGES-1) inhi- bition from cyclooxygenase-2 inhibition in cells using a novel, selective mPGES-1 inhibitor. Biochem Pharmacol. 2010 May 15;79(10):1445-54. doi: 10.1016/j.bcp. 2010.01.003. Epub 2010 Jan 11. 107. O'Byrne PM. Asthma treatment: antileukotriene drugs. Can Respir J. 1998 Jul- Aug;5 Suppl A:64A-70A. 108. Cingi C, Muluk N, Ipci K, Sahin E. Antileukotrienes in upper airway inflammato- ry diseases. Curr Allergy Asthma Rep. 2015 Nov; 15(11):64. doi: 10.1007/s11882-015-0564-7. 109. Kulkarni SK, Singh VP. Licofelone: the answer to unmet needs in osteoarthritis thera- py? Curr Rheumatol Rep. 2008 Jan;10(1):43-8. 110. Bertolini A, Ottani A, Sandrini M. Dual acting anti-inflammatory drugs: a reappraisal. Pharmacol Res. 2001 Dec;44(6):437-50. 111. Raynauld JP, Martel-Pelletier J, Bias P, et al. Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI. Ann Rheum Dis. 2009 Jun;68(6):938-47. doi: 10.1136/ard. 2008.088732. Epub 2008 Jul 23. 112. Blake D, Robson P, Ho M, et al. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford). 2006 Jan;45(1):50-2. Epub 2005 Nov 9. 113. Elati A, Weeks AD. The use of misopros- tol in obstetrics and gynaecology. BJOG. 2009 Oct;116 Suppl 1:61-9. doi: 10.1111/j.1471- 0528.2009.02329.x. 114. Linet OI, Ogrine FG. Efficacy and safety of intracavernosal alprostadil in men with erec- tile dysfunction. The Alprostadil Study Group. N Engl J Med. 1996 Apr 4;334(14):873-7. 115. Woodward DF, Wang JW, Poloso NJ. Recent progress in prostaglandin F2 α ethanolamide (prostamide F2 α) research and therapeutics. Pharmacol Rev. 2013 Jul 26;65(4):1135-47. doi: 10.1124/pr.112. 007088. Print 2013. 116. LeVarge BL. Prostanoid therapies in the management of pulmonary arterial hyperten- sion. Ther Clin Risk Manag. 2015 Mar 31;11:535-47. doi: 10.2147/TCRM.S75122. eCollection 2015. 117. Cholkar K, Gilger BC, Mitra AK. Topical delivery of aqueous micellar resolvin E1 analog (RX-10045). Int J Pharm. 2016 Feb 10;498(1-2):326-34. doi: 10.1016/j.ijpharm. 2015.12.037. Epub 2015 Dec 17. |